Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% reduction in progression or death. The MajesTEC-9 trial highlights ...
Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where all blood cells are produced. Plasma cells are a type of white blood cell that ...
Stage 2 multiple myeloma involves intermediate cancer levels, requiring treatment for symptoms like bone issues, anemia, and kidney problems. Diagnosis includes blood, urine, imaging tests, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback